The SAFEPAX drug coating provides a superior drug coating quality ahead of most contemporary first and second generation DCB coatings.

Available on: LEGFLOW DCB, RESTORE DCB & APERTO Shunt DCB

VIRTUALLY LOSS-LESS MATRIX FOR IMPROVED HOMOGENEITY OF DRUG TRANSFER AND HIGHEST COATING STABILITY ON THE MARKET*

* Cardionovum data on file

When invisibility equals safety!
‘Stable’ vs. ‘unstable’ DCB PTX coating.

  1. Homogeneous surface composed of smooth amorphous coating: 'solid solution’ of PTX /Ammonium Salt excipient

  2. Balloon surface coated with white powder of brittle crystalline
    PTX + excipients

Microscopy of the ‘SAFEPAX’ balloon surface
showing no visible PTX particulates.
Minimizing the risk of thrombotic effect.

SAFEPAX® the 3rd generation unique paclitaxel matrix system, with Lipophilic and Polymeric excipient to minimize wash off rate and prevent drug crystallization on the balloon's surface incorporates PTX drug in a homogeneous non-crystalline coating.

Is Your DCB really the right choice?
Please inform yourself about your treatment option!

No drug coating pitfalls but only high performance.
SAFEPAX provides superior patient results!

Clinically important
drug coating features:

SAFEPAX COATING INTEGRITY:
Stable, elastic polymeric and lipophilic coating with low surface friction for easy handling. After crossing the hemostatic valve, no coating debris are observed at microscope*, no loading tool is required.

*Cardionovum data on file

SAFEPAX SAFETY:

  • No safety issues with Cardionovum DCBs in clinical trials and registries to date.
  • SAFEPAX ® has the highest coating stability (Paclitaxel loss during handling & wash-off) of DCBs without compromising performance.*
  • In blood simulated test, Cardionovum DCBs demonstrated high coating stability and minimal particulate loss.*

    *Cardionovum data on file. Reports are available upon request

SAFEPAX PERFORMANCE:
Consistent and predictable drug delivery to the artery lesion site results in a homogenous and maximized drug absorption into the arterial tissue.

THE UNIQUE SAFEPAX INNOVATION:
The step beyond contemporary first and second generation DCB coatings which had to compromise on vulnerable balloon coating mixtures out of a high water soluble drug excipient with relatively large PTX crystals.

go top